Oportuzumab monatox is an antibody-drug conjugate that targets epithelial cell-adhesion molecule (EpCAM) in development for the treatment of bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. It is an intravesical treatment, administered through a catheter directly into the bladder.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis
Focus of the Report: This report focuses on the use of fecal microbiota transplantation (FMT) to treat adults with ulcerative colitis (UC).
Technology Description: FMT is a procedure by which processed stool from healthy donors is infused into a patient’s gastrointestinal (GI) system for the purpose of treating a disease associated with impaired gut mi…
Viveve System for Stress Urinary Incontinence in Women
The Viveve System is a cryogen-cooled monopolar radiofrequency device proposed for treatment of stress urinary incontinence in premenopausal women.
Sotos Syndrome
This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for Sotos syndrome.
Ellipsys Vascular Access System (Avenu Medical) in Patients with End-Stage Renal Disease
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Ellipsys Vascular Access System (VAS) for the creation of arteriovenous fistula (AVF) in patients who undergo hemodialysis.
Saphnelo (Anifrolumab-fnia) for Systemic Lupus Erythematosus
Saphnelo (anifrolumab-fnia) is a fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of all type I IFNs. It is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
Intravenous Immunoglobulin (IVIG) for Treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of intravenous immunoglobulin (IVIG) for treatment of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS).
Oncotype DX AR-V7 Nucleus Detect (Epic Sciences)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX AR-V7 Nucleus Detect test.
Retifanlimab for Squamous Cell Anal Cancer
Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system response against certain cancers. Retifanlimab is proposed as a monotherapy for locally advanced and metastat…
Triamcinolone Acetonide Extended-Release (Zilretta) for the Management of Knee Osteoarthritis
Focus of the Report: The use of Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of pain associated with knee osteoarthritis (KOA).
Technology Description: Zilretta (Flexion Therapeutics Inc.) is an extended-release intra-articular therapy for pat…